F20 - Manage Severe Insulin Resistance the Smart Way

Friday, August 9, 2024

2:55 PM – 3:40 PM CT

CE/CME Hours: .75

CE/CME Hours: .75
Pharmacology Hours: .50
Activity Type: Knowledge
UAN: JA4008258-0000-24-091-L01-P
CHES/MCHES: .75

Insulin resistance is a hallmark of type 2 diabetes and is defined as insulin requirements of >1 unit/kg/day. People who require >200 units/day, or >2 units/kg/day, are considered to have severe insulin resistance. Strategies to optimize glycemic management in this population include concentrated insulin (U-500, U-300) as well as combinations with insulin-sensitizing agents like GLP-1 receptor agonists, metformin, or thiazolidinediones. For those with significantly diminished endogenous insulin production, smart technologies (insulin pumps with CGM) offer new treatment options. This presentation will use case studies to discuss practical strategies to effectively manage severe insulin resistance.

Primary Presenter(s)

Evan Sisson, PharmD, MSHA, BCACP, CDCES, FADCES

Professor
VCU School of Pharmacy
Richmond, Virginia

Disclosure(s): No financial relationships to disclose

Slides Slide Player

Co-Presenter(s)

Dana Burns, DNP, FNP-BC, BC-ADM

Clinical Associate Professor
VCU School of Nursing
Richmond, Virginia

Disclosure(s): No financial relationships to disclose

Moderator(s)

Jennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM (she/her/hers)

Clinical Professor and Director of Pharmacy Education
University of South Carolina College of Pharmacy
Simpsonville, South Carolina

Disclosure(s): Eli Lilly (Zepbound): Speakers' Bureau (Ongoing); Novo Nordisk (Ozempic, Rybelsus): Speakers' Bureau (Ongoing)